Design of a phase II allergen immunotherapy study to determine the optimally effective and safe dose of subcutaneously administered tyrosine adsorbed modified grass allergen + MPL

Zielen S., Kuna P., Aberer W., Lassmann S., Wade A., Kluehr K., Raab J., Lee D., Ballard R., Jones C., Gunawardena K., Higenbottam T., Skinner M.A. EAACI, Munich, 2018